Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease
NCT04826172 is registered in ClinicalTrials.gov with Imbria Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease
- Lead sponsor
- Imbria Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 23, 2021
- Completion date
- September 21, 2023
- Enrollment
- 58 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.